Skip to content
Welcome to Heart Matters - Empowering Heart Health
Research Insights

Leadless Pacemakers: Advancing Cardiac Care with Promising Results

Pacemakers are essential devices for maintaining a steady heartbeat, particularly in bradycardia cases. They typically consist of a skin-implanted generator connected to the heart via leads, which regulate its rhythm through electrical signals. Innovations like leadless pacemakers, directly implanted in the heart, minimize lead-related complications. While limitations remain, these advancements promise an exciting future for cardiac pacing.

 

Traditional Pacemakers with Leads

Modern cardiac pacing often employs pacemakers containing a generator and one or more leads. These leads thread through the heart, transmitting electrical signals for rhythm regulation, mainly in the right atrium and right ventricle.

Recent progress highlights the effectiveness of leadless pacemakers, displaying promising outcomes. In this article, we’ll explore the pros and cons of leadless pacemakers versus traditional generator-and-leads methods. This underscores the substantial potential of leadless pacemakers in shaping cardiac care’s future landscape.

Figure 1: Conventional Pacemaker Setup Conventional pacemakers comprise a generator can and leads. The leads establish a connection with the generator and are routed through the veins to the right side of the heart. This configuration enables the transmission of electrical signals to regulate the heart’s rhythm in cases of slow heart rate or related conditions.

 

Leadless Pacemakers

Leadless pacemakers are small, self-contained devices that are implanted directly into the heart. Unlike traditional pacemakers, which require leads to be threaded through veins into the heart, leadless pacemakers are placed directly in the right ventricle or atrium. This innovative design offers several advantages over their traditional counterparts.

Figure 2: Illustrates the configuration of a typical leadless pacemaker. Unlike conventional pacemakers that involve leads threading through the heart, leadless pacemakers are designed to be self-contained units implanted directly within the heart. This compact design eliminates the need for leads and simplifies the overall pacing setup. The figure showcases how leadless pacemakers represent a streamlined and minimally invasive option for cardiac pacing

 

Configuration, Advantages, and Limitations

As a cardiologist, I find the leadless pacemaker technology undeniably intriguing, albeit in a phase of ongoing evolution. Until fairly recently, these pacemakers have found their primary utility in cases where a single lead from a conventional pacemaker suffices – typically among patients with underlying atrial fibrillation. It’s worth noting that adopting this technology involves a learning curve to accumulate experience, and the upfront cost is comparatively higher than that of conventional options. Despite these considerations, the prospects offered by leadless pacemakers are indeed noteworthy and warrant continued exploration.

Reduced Risk of Lead-Related Complications: One of the primary benefits of leadless pacemakers is the elimination of pacing leads. Traditional pacemakers with leads carry a small risk of lead fracture, dislodgement, or infection. Leadless pacemakers mitigate these risks, reducing the need for lead-related interventions.

Minimally Invasive Procedure: The implantation of leadless pacemakers involves a minimally invasive procedure compared to traditional pacemakers. This results in shorter hospital stays, faster recovery times, and decreased discomfort for patients.

Improved Aesthetics and Comfort: The smaller size and lack of visible leads make leadless pacemakers more discreet and comfortable for patients. They eliminate the need for a visible pocket under the skin, reducing self-consciousness and improving overall quality of life.

Longevity and Battery Life: Leadless pacemakers have demonstrated impressive battery longevity, with some models designed to last over a decade. This eliminates the need for frequent battery replacements and reduces the long-term maintenance burden on patients.

Limited Functionality: Currently, leadless pacemakers are primarily single-chamber devices, providing pacing only to the ventricles or atria. This limits their application to patients who require single-chamber pacing. However, the recent study on dual chamber leadless pacemakers suggests potential advancements in this area and offers a very exciting future for cardiac pacing.

Higher Cost: Leadless pacemakers tend to be more expensive than traditional pacemakers due to their advanced technology and specialized design. While the long-term benefits may outweigh the initial cost, this aspect should be considered during treatment planning.

Availability: Leadless pacemakers are still relatively new in the market and may not be widely available in all healthcare facilities. However, as their efficacy becomes more established, their accessibility is expected to increase.

 

New Research Insights

The recent study titled “Safety, Performance, and Synchrony With Dual-Chamber Leadless Cardiac Pacing,” published in the New England Journal of Medicine on May 20, 2023, assesses the safety and effectiveness of a percutaneously implanted dual-chamber leadless pacemaker system in the right atrium and right ventricle of patients who conventionally require dual-chamber pacing. Conducted by the Aveir DR i2i Study Investigators and supported by Abbott Medical, this study examines a novel pacemaker system comprising two heart-implanted devices.

The study focused on evaluating the safety and functionality of this new pacemaker system designed for dual-chamber pacing, addressing both the atrium and ventricle. The findings revealed that the pacemaker system exhibited safety and reliable pacing capabilities for a three-month period post-implantation. However, it’s important to acknowledge the study’s limitation of short-term follow-up, emphasizing the need for extended observation to comprehensively assess the safety and efficacy of this innovative pacemaker system. According to the study, a dual-chamber leadless pacemaker system might surpass lead-based counterparts due to various considerations.

The authors conclude that leadless pacemakers eliminate the need for transvenous leads and the generator pocket, which reduces the long-term risk of infection and lead malfunction that affects one in six patients during 3 years of follow-up. 

In contrast to single-chamber ventricular leadless pacemakers, the dual-chamber system offers atrial pacing and consistent atrioventricular synchrony. This broadens the scope of leadless pacemaker therapy. In the study, the dual-chamber system successfully achieved the primary safety goal and sustained atrial pacing along with reliable atrioventricular synchrony for three months post-implantation. The investigator suggests that this dual-chamber leadless pacemaker system could present a safer, more dependable, and adaptable alternative to conventional lead-based pacemakers.

 

Conclusion

The recent study highlighting the positive outcomes of dual chamber leadless pacemakers marks a significant milestone in cardiac care. While these pacemakers offer various benefits like reduced risk of lead-related complications, minimally invasive procedures, enhanced aesthetics, and longer battery life, they also present limitations, including restricted functionality and higher costs. Evaluating these pros and cons is essential for healthcare providers and patients when choosing the appropriate pacemaker option. With technology’s continuous advancement, leadless pacemakers hold considerable promise in enhancing patient outcomes and revolutionizing cardiac care. Ongoing research and technological advancement should alleviate limitations, expanding leadless pacemaker potential for a wider patient population.
 

About the author

Heart Matters, edited by cardiologist Professor Peter Barlis, is a trusted resource that offers clear and accurate information on cardiovascular health. It bridges the gap between scientific research and everyday understanding, empowering you to make informed choices and take an active role in supporting your heart health.

Our Youtube Channel

Discover our Heart Matters YouTube channel, where we bring heart health to life. From explaining common conditions and symptoms to discussing the latest research, our engaging videos simplify complex topics, ensuring you have access to valuable knowledge for a healthier heart. Subscribe now and embark on a journey of education, empowerment, and inspiration.

Editor's Picks

informing hearts
empowering lives

Subscribe to our newsletter and be the first to receive valuable insights, tips, and resources on heart health.

other anti-anginals

When first-line therapies for angina, such as beta blockers, calcium channel blockers, and nitrates, prove inadequate or are not well-tolerated, second-line therapies may be considered.
Perhexiline is a unique medication that enhances the heart's ability to utilize fatty acids for energy, reducing its reliance on oxygen and lowering oxygen demand. This action helps improve blood flow and alleviates chest pain in some patients with refractory angina.
Nicorandil is another second-line option with a dual mechanism of action. It opens potassium channels in smooth muscle cells, causing vasodilation and enhancing coronary blood flow. Additionally, nicorandil also stimulates nitric oxide release, further dilating blood vessels and reducing heart workload.
Trimetazidine is an anti-ischemic agent that improves cardiac efficiency by enhancing glucose metabolism and shifting the heart's energy production to a more oxygen-efficient process. As second-line therapies, these medications offer alternative approaches for managing angina in individuals who do not respond adequately to first-line treatments or those experiencing side effects from other medications.

lipid lowering therapies

Lipid-lowering therapies are essential in managing coronary artery disease (CAD), a condition where the arteries supplying blood to the heart become narrowed. Among the most commonly prescribed treatments are statins, which reduce cholesterol production in the liver and significantly lower the risk of heart attacks and strokes.

Other medications may be used to target different aspects of lipid metabolism:

  • Ezetimibe helps reduce the absorption of cholesterol in the gut
  • Fibrates lower triglyceride levels
  • Niacin can help raise high-density lipoprotein (HDL) cholesterol

In recent years, a newer class of medications known as PCSK9 inhibitors—such as Repatha (evolocumab)—has become available. These drugs block a specific enzyme involved in cholesterol regulation and can dramatically lower LDL cholesterol, particularly in patients who do not achieve target levels with statins alone.

Together, these therapies provide a range of options to personalise treatment and improve cardiovascular outcomes.

Nitrates

Nitrates for Angina Relief

Nitrates are widely used to treat angina and provide quick relief from chest pain. These medications are commonly available as sublingual sprays or tablets, skin patches, and long-acting tablets.

Nitrates work by dilating blood vessels, allowing for increased blood flow and reduced vascular resistance. This reduces the heart’s workload and lowers its oxygen demand, offering prompt relief from angina symptoms.

Sublingual nitrates act quickly and are typically used at the onset of angina symptoms, while patches and long-acting tablets are used for ongoing prevention.

Common side effects include headaches, dizziness, and flushing. These often improve with continued use but should be discussed with a healthcare provider if persistent or bothersome.

calcium channel blockers

Calcium channel blockers, including amlodipine, felodipine, Cardizem (diltiazem), and verapamil, are commonly prescribed for the treatment of angina.

These medications work by inhibiting the influx of calcium into the muscle cells of the heart and blood vessels, causing them to relax. This relaxation leads to the widening of blood vessels, which improves blood flow and reduces blood pressure.

For individuals with angina, calcium channel blockers reduce the heart’s workload and oxygen demand, helping to relieve chest pain and prevent angina episodes.

While effective, they may cause side effects such as headaches, dizziness, facial flushing, and ankle swelling. These effects should be monitored and discussed with your healthcare provider if they persist.

Beta blockers

Beta blockers, such as metoprolol, propranolol, atenolol, carvedilol, and bisoprolol, play a crucial role in managing angina.

These medications work by blocking specific receptors in the heart, which slows the heart rate and reduces the strength of each contraction. This results in a lower oxygen demand by the heart and helps relieve chest pain associated with angina.

Beta blockers are highly effective in both relieving symptoms and preventing angina episodes. However, they may cause side effects in some individuals, including tiredness, worsened asthma symptoms, more vivid dreams, and erectile dysfunction in some males.

It is important to consult your healthcare provider to determine whether beta blockers are a suitable option for your angina and overall heart health.

Anti-platelet Medications

Anti-platelet medications play a crucial role in preventing blood clot formation and reducing the risk of serious cardiovascular events such as heart attacks and strokes. Commonly used agents include aspirin, clopidogrel, and ticagrelor.

 

Aspirin: This well-known medication inhibits platelet activation, reducing the likelihood that platelets will clump together and form clots. It is widely used for both primary and secondary prevention of heart attacks and strokes.

 

Clopidogrel: A potent anti-platelet agent, clopidogrel works by blocking specific receptors on platelets to prevent aggregation. It is commonly prescribed for patients with acute coronary syndrome, those undergoing stent placement, and some individuals with peripheral arterial disease.

 

Ticagrelor: Ticagrelor also inhibits platelet activation and is typically used in the treatment of acute coronary syndrome. It is often prescribed alongside aspirin to provide dual anti-platelet therapy and further reduce the risk of heart-related events.